These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19556991)

  • 1. Dialysis: Phosphorus binders and survival: need for randomized trials.
    Ix JH; Chertow GM
    Nat Rev Nephrol; 2009 Jul; 5(7):368-70. PubMed ID: 19556991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorus binders and survival on hemodialysis.
    Isakova T; Gutiérrez OM; Chang Y; Shah A; Tamez H; Smith K; Thadhani R; Wolf M
    J Am Soc Nephrol; 2009 Feb; 20(2):388-96. PubMed ID: 19092121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of time-varying albumin and phosphorus on mortality in incident dialysis patients.
    Zitt E; Lamina C; Sturm G; Knoll F; Lins F; Freistätter O; Kronenberg F; Lhotta K; Neyer U
    Clin J Am Soc Nephrol; 2011 Nov; 6(11):2650-6. PubMed ID: 21903986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials.
    Wang F; Lu X; Zhang J; Xiong R; Li H; Wang S
    Kidney Blood Press Res; 2018; 43(2):536-544. PubMed ID: 29627829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
    St Peter WL; Wazny LD; Weinhandl ED
    Am J Kidney Dis; 2018 Feb; 71(2):246-253. PubMed ID: 29195858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial.
    Shahbazian H; Zafar Mohtashami A; Ghorbani A; Abbaspour MR; Belladi Musavi SS; Hayati F; Lashkarara GR
    Nefrologia; 2011; 31(1):58-65. PubMed ID: 21270914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Education for dialysis patients lowers long-term phosphate levels and maintains health-related quality of life.
    Gardulf A; Pålsson M; Nicolay U;
    Clin Nephrol; 2011 Apr; 75(4):319-27. PubMed ID: 21426886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotinic acid and nicotinamide: a review of their use for hyperphosphatemia in dialysis patients.
    Rennick A; Kalakeche R; Seel L; Shepler B
    Pharmacotherapy; 2013 Jun; 33(6):683-90. PubMed ID: 23526664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis.
    El Borolossy R; El Wakeel LM; El Hakim I; Sabri N
    Pediatr Nephrol; 2016 Feb; 31(2):289-96. PubMed ID: 26420678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineral metabolism and mortality in dialysis patients: a reassessment of the K/DOQI guideline.
    Noordzij M; Korevaar JC; Dekker FW; Boeschoten EW; Bos WJ; Krediet RT; Bossuyt PM; Geskus RB;
    Blood Purif; 2008; 26(3):231-7. PubMed ID: 18305386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis.
    Vegter S; Tolley K; Keith MS; Postma MJ
    Value Health; 2011; 14(6):852-8. PubMed ID: 21914505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.
    Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ
    Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes.
    Bhandari SK; Liu IA; Kujubu DA; Huynh T; Behayaa H; Kovesdy CP; Kalantar-Zadeh K; Jacobsen SJ; Sim JJ
    Am J Nephrol; 2017; 45(5):431-441. PubMed ID: 28445887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.
    Block GA; Hulbert-Shearon TE; Levin NW; Port FK
    Am J Kidney Dis; 1998 Apr; 31(4):607-17. PubMed ID: 9531176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies of the Various Chronic Kidney Failure Rat Models and Hemodialysis Mini-pig Model for the Evaluation of Anti-hyperphosphatemia Drugs].
    Okabe T; Katoh M; Kano M; Okazaki R; Tanaka Y; Toyoda H; Ueno M
    Yakugaku Zasshi; 2019; 139(11):1435-1448. PubMed ID: 31685740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.